p53 expression in circulating lymphocytes of non-melanoma skin cancer patients from an arsenic contaminated region in Mexico. A pilot study

Molecular and Cellular Biochemistry

Volumn 255, Issue 1-2, 2004, Pages 25-31

  Salazar, Ana M ^a   Calderón Aranda, Emma ^b   Cebrián, Mariano E ^b   Sordo, Monserrat ^a   Bendesky, Andrés ^a,c   Gómez Muñoz, Arístides ^b   Acosta Saavedra, Leonor ^b   Ostrosky Wegman, Patricia ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Arsenic exposure; p53 protein; Skin cancer

Indexed keywords

ARSENIC; BIOLOGICAL MARKER; DRINKING WATER; PROTEIN P53;

ADULT; AGED; CANCER CLASSIFICATION; CANCER PATIENT; CHEMICAL CARCINOGENESIS; CHRONIC TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MEXICO; PERIPHERAL LYMPHOCYTE; PILOT STUDY; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SAMPLE SIZE; SKIN CANCER; SKIN CARCINOGENESIS; WATER CONTAMINATION;

ARSENIC; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOCYTES; MALE; MELANOMA; MEXICO; PILOT PROJECTS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; WATER POLLUTION, CHEMICAL;

EID: 0742306718     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000007258.33942.f8     Document Type: Review

References (45)

1. Jager JW, Ostrosky-Wegman P: Arsenic: A paradoxical human carcinogen. Mutat Res 386: 181-184, 1997
2. Chen CJ, Chen CW, Wu MM, Kuo TL: Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66: 888-892, 1992
3. Chiou HY, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS-N, Huang CH, Chen CJ: Incidence of internal cancer and ingested inorganic arsenic: A seven-year follow-up study in Taiwan. Cancer Res 55: 1296-1300, 1995
4. NRC National Research Council: Arsenic in Drinking Water. National Academy Press, Washington DC, 1999
5. Chowdhury UK, Biswas BK, Chowdhury TR, Samanta G, Mandal BK, Basu GC, Chanda CR, Lodh D, Saba KC, Mukherjee SK, Roy S, Kabir S, Quamruzzaman Q, Chakraborti D: Groundwater arsenic contamination in Bangladesh and West Bengal, India: Environ Health Perspect 108: 393-397, 2000
6. Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, Hopenhayn-Rich C, Shimojo N: Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 110: 331-336, 2002
7. Smith AH, Goycolea M, Haque R, Biggs ML: Marked increase in bladder and lung cancer mortality in a region of northern Chile due to arsenic in drinking water. Am J Epidemiol 147: 660-669, 1998
8. Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S: Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40: 453-463, 1968
9. Yeh S: Skin cancers in chronic arsenicism. Hum Pathol 4: 469-485, 1973
10. Cöl M, Cöl C, Soran A, Sayli BS, Öztürk S: Arsenic-related Bowen's disease, palmar keratosis, and skin cancer. Environ Health Perspect 107: 687-689, 1999
11. Sommers SC, McManus RG: Multiple arsenical cancers of the skin and internal organs. Cancer 6: 347-359, 1953
12. Cebrian ME, Albores A, Aguilar M, Blakely E: Chronic arsenic poisoning in the North of Mexico. Human Toxicol 2: 121-133, 1983
13. Germolac DR, Spalding J, Boorman GA, Wilmer JL, Yoshida T, Simmeonova PP, Brucccoleri A, Kayama F, Gaido K, Tennant R, Burleson F, Dong W, Lang RW, Luster MI: Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res 386: 209-218, 1997
14. Kaltreider RC, Davis AM, Lariviere JP, Halmilton JW: Arsenic alters the function of the glucocorticoid receptor as a transcription factor. Environ Health Perspect 109: 245-251, 2001
15. Parrish AR, Zheng XH, Turkey KD, Younis HS, Gandolfi AJ: Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol Sci 50: 98-105, 1999
16. Salazar AM, Ostrosky-Wegman P, Menéndez D, Miranda E, García-Carrancá A, Rojas E: Induction of p53 protein expression by sodium arsenite. Mutat Res 381: 259-265, 1997
17. Zhong CX, Mass MJ: Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol Lett 122: 223-234, 2001
18. Lu T, Liu J, LeCluyse EL, Zhou YS, Cheng ML, Waalkes MP: Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci 59: 185-192, 2001
19. Hsu CH, Yang SA, Wang JY, Yu HS, Lin SR: Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer 80: 1080-1086, 1999
20. Kuo TT, Hu S, Lo SK, Chan HL: p53 expression and proliferative activity in Bowen's disease with or without chronic arsenic exposure. Human Pathol 28: 786-790, 1997
21. Gonsebatt ME, Vega L, Herrera LA, Montero R, Rojas E, Cebrián ME, Ostrosky-Wegman P: Inorganic arsenic effects on human lymphocyte stimulation and proliferation. Mutat Res 283: 91-95, 1992
22. Gonsebatt ME, Vega L, Montero R, Garcia-Vargas G, Del Razo LM, Albores A, Cebrian ME, Ostrosky-Wegman P: Lymphocyte replicating ability in individuals exposed to arsenic via drinking water. Mutat Res 313: 293-299, 1994
23. Del Razo LM, Arellano MA, Cebrián ME: The oxidation states of arsenic in well-water from a chronic arsenicism area of northern Mexico. Environ Pollut 64: 143-153, 1990
24. Del Razo LM, García-Vargas G, Vargas H, Albores A, Gonsebatt ME, Montero R, Ostrosky-Wegman P, Kelsh M, Cebrián M: Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. Arch Toxicol 71: 211-217, 1997
25. Gonsebatt ME, Vega L, Salazar AM, Montero R, Guzmán P, Blas J, Del Razo LM, García-Vargas G, Albores A, Cebrián ME, Kelsh M, Ostrosky-Wegman P: Cytogenetic effects in human exposure to arsenic. Mutat Res 386: 219-228, 1997
26. Méplan C, Richard MJ, Hainaut P: Redox signalling and transition metals in the control of the p53 pathway. Biochemical Pharmacol 59: 25-33, 2000
27. Kaczmarek L, Calabretta B, Baserga R: Expression of cell-cycle-dependent genes in phytohemagglutinin-stimulated human lymphocytes. Proc Natl Acad Sci 82: 5375-5379, 1985
28. Reed J, Nowell P, Hoover R: Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation. Proc Natl Acad Sci 82: 4221-4224, 1985
29. Reed J, Alpers J, Nowell P, Hoover R: Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci 83: 3982-3986, 1986
30. Terada N, Lucas JJ, Gelfand WE: Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53 during cell cycle progression of normal human T cells. J Immunol 147: 698-704, 1991
31. Fukao T, Kaneko H, Birrell G, Gatei M, Tashita H, Yoshida T, Cross S, Kedar P, Watters D, Khana KK, Misko I, Kondo N, Lavin M: ATM is upregulated during the mitogenic response in peripheral blood mononuclear cells. Blood 6: 1998-2006, 1999
32. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T: Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 192: 48-53, 1999
33. Boonchai W, Walsh M, Chenevix-Trench G: Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch Dermatol 136: 195-198, 2000
34. Chang CH, Tsai RK, Chen GS, Yu HS, Chai CY: Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers. J Cutan Pathol 25: 457-462, 1998
35. Giaccia JA, Kastan BM: The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Development 12: 2973-2983, 1998
36. Vega L, Gonsebatt ME, Ostrosky-Wegman P: Aneugenic effect of sodium arsenite on human lymphocytes in vitro: An individual susceptibility effect detected. Mutat Res 334: 365-373, 1995
37. Yager JW, Wiencke JK: Inhibition of poly (ADP-ribose) polymerase by arsenite. Mutat Res 386: 345-351, 1997
38. Li JH, Rossman TG: Inhibition of DNA ligase activity by arsenite: A possible mechanism of its comutagenesis. Mol Toxicol 2: 1-9, 1989
39. Vega L, Ostrosky-Wegman P, Fortoul T, Díaz C, Madrid V, Saavedra R: Sodium arsenite reduces proliferation of human activated T-cells by inhibition of secretion of interleukin-2. Immunopharmacol Immmunotoxicol 21: 203-220, 1999
40. Orson FM, Saadeh CK, Lewis DE, Nelson DL: Interleukin 2 receptor expression by T cells in human aging. Cell Immunol 124: 278-291, 1989
41. Penn I: Tumors of the immunocompromised patient. Annu Rev Med 39:63-73, 1988
42. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nature 3: 991-998, 2002
43. Farmer JG, Johnson LR: Assessment of occupational exposure to inorganic arsenic based on urinary concentrations and speciation of arsenic. Br J Ind Med 47: 342-348, 1990
44. Rossman TG, Uddin AN, Burns FJ, Bosland MC: Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 176: 64-71, 2001
45. Cantemir C, Cozmei C, Scutaru B, Nicoara S, Carasevici E: p53 protein expression in peripheral lymphocytes from atrazine chronically intoxicated rats. Toxicol Lett 93: 87-94, 1997